Publications

Akram M, Hauser D, Dietl A, Steigleder M, Ullmann GM, Barends TRM
Redox potential tuning by calcium ions in a novel c-type cytochrome from an anammox organism
Journal of Biological Chemistry. 2025; 301(2): 108082 (15 pp.). https://doi.org/10.1016/j.jbc.2024.108082
DORA PSI

Benjamin JS, Jarret A, Bharill S, Fontanillas P, Yadav S, Sen D, et al.
23ME-01473, an Fc Effector–Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell–Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation
Cancer Research Communications. 2025; 5(4): 477-496. https://doi.org/10.1158/2767-9764.CRC-24-0478
DORA PSI

Chen JL, Methot JL, Mitcheltree MJ, Musacchio A, Corcoran EB, Feng G, et al.
The discovery of bridged benzoazepine amides as selective allosteric modulators of RIPK1
ACS Medicinal Chemistry Letters. 2025; 16(5): 811-818. https://doi.org/10.1021/acsmedchemlett.5c00063
DORA PSI

Coriolano A, Moliterni A, Todisco F, Polimeno L, Mastria R, Olieric V, et al.
Revealing the true nature of double-peak emission in 2D perovskite single crystals using polariton waveguides
Advanced Optical Materials. 2025. https://doi.org/10.1002/adom.202500299
DORA PSI

Gazzi T, Brennecke B, Olikauskas V, Hochstrasser R, Wang H, Keen Chao S, et al.
Development of a highly selective NanoBRET probe to assess MAGL inhibition in live cells
ChemBioChem. 2025; 26(6): e202400704 (7 pp.). https://doi.org/10.1002/cbic.202400704
DORA PSI

Hauseman ZJ, Stauffer F, Beyer KS, Mollé S, Cavicchioli E, Marchand JR, et al.
Targeting the SHOC2–RAS interaction in RAS-mutant cancers
Nature. 2025; 642: 232-241. https://doi.org/10.1038/s41586-025-08931-1
DORA PSI

Hentsch A, Guberman M, Radetzki S, Kaushik S, Huizenga M, He Y, et al.
Highly specific miniaturized fluorescent monoacylglycerol lipase probes enable translational research
Journal of the American Chemical Society. 2025; 147(12): 10188-10202. https://doi.org/10.1021/jacs.4c15223
DORA PSI

Kondo Y, Hatton C, Cheng R, Trabuco M, Glover H, Bertrand Q, et al.
Apo-state structure of the metabotropic glutamate receptor 5 transmembrane domain obtained using a photoswitchable ligand
Protein Science. 2025; 34(7): e70104 (8 pp.). https://doi.org/10.1002/pro.70104
DORA PSI

Kunieda K, Nagiri C, Watanabe M, Yoshida T, Zou J, Kaneda A, et al.
A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects
American Journal of Cancer Research. 2025; 15(5): 2097-2110. https://doi.org/10.62347/JCGQ1004
DORA PSI

Loyau J, Monney T, Montefiori M, Bokhovchuk F, Streuli J, Blackburn M, et al.
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
mAbs. 2025; 17(1): 2457471 (26 pp.). https://doi.org/10.1080/19420862.2025.2457471
DORA PSI

Milgram BC, Borrelli DR, Brooijmans N, Henderson JA, Hilbert BJ, Huff MR, et al.
Discovery of STX-721, a covalent, potent, and highly mutant-selective EGFR/HER2 exon20 insertion inhibitor for the treatment of non-small cell lung cancer
Journal of Medicinal Chemistry. 2025; 68(3): 2403-2421. https://doi.org/10.1021/acs.jmedchem.4c02377
DORA PSI

Namoto K, Vangrevelinghe E, Machauer R, Behnke D, Buschmann N, Lachal J, et al.
Discovery and optimization of selective inhibitors of large tumor suppressor kinases LATS1 and 2 for in vivo investigation of the Hippo-YAP pathway in tissue regeneration
Journal of Medicinal Chemistry. 2025; 68: 13591-13608. https://doi.org/10.1021/acs.jmedchem.5c00350
DORA PSI

Pagliarini RA, Henderson JA, Milgram BC, Borrelli DR, Brooijmans N, Hilbert BJ, et al.
STX-721, a covalent EGFR/HER2 Exon 20 inhibitor, utilizes exon 20–mutant dynamic protein states and achieves unique mutant selectivity across human cancer models
Clinical Cancer Research. 2025. https://doi.org/10.1158/1078-0432.CCR-24-3833
DORA PSI

Ramberg KO, Boland C, Kooshapur H, Soubias O, Wiktor M, Huang CY, et al.
Solid-state NMR of membrane peptides and proteins in the lipid cubic phase
Biophysical Journal. 2025; 124(9): 1387-1400. https://doi.org/10.1016/j.bpj.2025.03.012
DORA PSI

Rothman AMK, Florentin A, Zink F, Quigley C, Bonneau O, Hemmig R, et al.
Therapeutic potential of allosteric HECT E3 ligase inhibition
Cell. 2025; 188(10): 2603-2620.e18. https://doi.org/10.1016/j.cell.2025.03.001
DORA PSI

Scaletti Hutchinson E, Martínez-Carranza M, Fu B, Mäler L, Stenmark P
Structure and membrane interactions of Arabidopsis thaliana DGD2, a glycosyltransferase in the chloroplast membrane
Journal of Biological Chemistry. 2025; 301(5): 108431 (12 pp.). https://doi.org/10.1016/j.jbc.2025.108431
DORA PSI

Schulz T, Gontla R, Teuber A, Beerbaum M, Fletcher BS, Mühlenberg T, et al.
Design, synthesis, and SAR of covalent KIT and PDGFRA inhibitors─exploring their potential in targeting GIST
Journal of Medicinal Chemistry. 2025; 68(3): 3238-3259. https://doi.org/10.1021/acs.jmedchem.4c02472
DORA PSI

Scott T, Smethurst CAP, Westermaier Y, Mayer M, Greb P, Kousek R, et al.
Drugit: crowd-sourcing molecular design of non-peptidic VHL binders
Nature Communications. 2025; 16(1): 3548 (11 pp.). https://doi.org/10.1038/s41467-025-58406-0
DORA PSI

Shen DM, Byth KF, Bertheloot D, Braams S, Bradley S, Dean D, et al.
Discovery of DFV890, a potent sulfonimidamide-containing NLRP3 inflammasome inhibitor
Journal of Medicinal Chemistry. 2025; 68(5): 5529-5550. https://doi.org/10.1021/acs.jmedchem.4c02759
DORA PSI

Terrosu S, Nurullina L, Supantanapong N, Pak BS, Nguyen S, Holm M, et al.
Synthesis of differentially halogenated lissoclimide analogues to probe ribosome e-site binding
ACS Chemical Biology. 2025; 20(4): 858-869. https://doi.org/10.1021/acschembio.4c00825
DORA PSI

Thoma G, Miltz W, Waelchli R, Orain D, Spanka C, Decoret O, et al.
Discovery of GJG057, a potent and highly selective inhibitor of leukotriene C4 synthase
Journal of Medicinal Chemistry. 2025. https://doi.org/10.1021/acs.jmedchem.4c02897
DORA PSI

Tivon B, Wiese J, Müller MP, Gabizon R, Rauh D, London N
Computational design of lysine targeting covalent binders using Rosetta
Journal of Chemical Information and Modeling. 2025; 65(11): 5612-5622. https://doi.org/10.1021/acs.jcim.5c00212
DORA PSI

Velcicky J, Cremosnik G, Scheufler C, Meier P, Wirth E, Felber R, et al.
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologies
Nature Communications. 2025; 16(1): 1669 (13 pp.). https://doi.org/10.1038/s41467-025-56601-7
DORA PSI

Velcicky J, Ngo E, Bauer MR, Meyer A, Schlapbach A, Racine S, et al.
Thiazole-based IL-17 inhibitors discovered by scaffold morphing
ChemMedChem. 2025; 20(7): e202400851 (8 pp.). https://doi.org/10.1002/cmdc.202400851
DORA PSI

Zak KM, Waterson AG, Geist L, Braun N, Hauer K, Rumpel K, et al.
Discovery of small molecules that bind to son of sevenless 2 (SOS2)
Journal of Medicinal Chemistry. 2025; 68(3): 2680-2693. https://doi.org/10.1021/acs.jmedchem.4c02007
DORA PSI

Zhang XC, Xue K, Salvi M, Schomburg B, Mehrens J, Giller K, et al.
Mechanism of sensor kinase CitA transmembrane signaling
Nature Communications. 2025; 16(1): 935 (11 pp.). https://doi.org/10.1038/s41467-024-55671-3
DORA PSI

Abel AC, Mühlethaler T, Dessin C, Schachtsiek T, Sammet B, Sharpe T, et al.
Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop
Journal of Biological Chemistry. 2024; 300(6): 107363 (10 pp.). https://doi.org/10.1016/j.jbc.2024.107363
DORA PSI

Aksu M, Kumar P, Güttler T, Taxer W, Gregor K, Mußil B, et al.
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters
Antiviral Research. 2024; 221: 105778 (21 pp.). https://doi.org/10.1016/j.antiviral.2023.105778
DORA PSI

Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, et al.
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Nature. 2024; 629(8011): 435-442. https://doi.org/10.1038/s41586-024-07318-y
DORA PSI

Bothe U, Günther J, Nubbemeyer R, Siebeneicher H, Ring S, Bömer U, et al.
Discovery of IRAK4 inhibitors BAY1834845 (zabedosertib) and BAY1830839
Journal of Medicinal Chemistry. 2024; 67: 1225-1242. https://doi.org/10.1021/acs.jmedchem.3c01714
DORA PSI

Butini S, Grether U, Jung KM, Ligresti A, Allarà M, Postmus AGJ, et al.
Development of potent and selective monoacylglycerol lipase inhibitors. SARs, structural analysis, and biological characterization
Journal of Medicinal Chemistry. 2024; 67(3): 1758-1782. https://doi.org/10.1021/acs.jmedchem.3c01278
DORA PSI

Carney DW, Leffler AE, Bell JA, Chandrasinghe AS, Cheng C, Chang E, et al.
Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity
Bioorganic and Medicinal Chemistry. 2024; 103: 117577 (27 pp.). https://doi.org/10.1016/j.bmc.2023.117577
DORA PSI

Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, et al.
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Nature Cancer. 2024; 5(7): 1102-1120. https://doi.org/10.1038/s43018-024-00754-9
DORA PSI

DeRatt LG, Zhang Z, Pietsch C, Cisar JS, Zhang X, Wang W, et al.
Discovery of JNJ-74856665: a novel isoquinolinone DHODH inhibitor for the treatment of AML
Journal of Medicinal Chemistry. 2024; 67: 11254-11272. https://doi.org/10.1021/acs.jmedchem.4c00809
DORA PSI

DeRatt LG, Pietsch EC, Cisar JS, Jacoby E, Kazmi F, Matico R, et al.
Discovery of alternative binding poses through fragment-based identification of DHODH inhibitors
ACS Medicinal Chemistry Letters. 2024; 15(3): 381-387. https://doi.org/10.1021/acsmedchemlett.3c00543
DORA PSI

DeRatt LG, Zhang Z, Pietsch EC, Cisar J, Wang A, Wang C yuan, et al.
Identification of isoquinolinone DHODH inhibitor isosteres
Bioorganic and Medicinal Chemistry Letters. 2024; 113: 129965 (7 pp.). https://doi.org/10.1016/j.bmcl.2024.129965
DORA PSI

Fernández-Quintero ML, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F, et al.
On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality
Protein Science. 2024; 33(11): e5176 (25 pp.). https://doi.org/10.1002/pro.5176
DORA PSI

Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al.
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Nature. 2024; 629(8011): 443-449. https://doi.org/10.1038/s41586-024-07350-y
DORA PSI

Gehl M, Demmer U, Ermler U, Shima S
Mutational and structural studies of (βα)₈-barrel fold methylene-tetrahydropterin reductases utilizing a common catalytic mechanism
Protein Science. 2024; 33(6): e5018 (18 pp.). https://doi.org/10.1002/pro.5018
DORA PSI

Glover H, Saßmannshausen T, Bertrand Q, Trabuco M, Slavov C, Bacchin A, et al.
Photoswitch dissociation from a G protein-coupled receptor resolved by time-resolved serial crystallography
Nature Communications. 2024; 15(1): 10837 (13 pp.). https://doi.org/10.1038/s41467-024-55109-w
DORA PSI

Goretzki B, Khoshouei M, Schröder M, Penner P, Egger L, Stephan C, et al.
Dual BACH1 regulation by complementary SCF-type E3 ligases
Cell. 2024; 187(26): 7585-7602.e25. https://doi.org/10.1016/j.cell.2024.11.006
DORA PSI

Gotthard G, Mous S, Weinert T, Maia RNA, James D, Dworkowski F, et al.
Capturing the blue-light activated state of the Phot-LOV1 domain from Chlamydomonas reinhardtii using time-resolved serial synchrotron crystallography
IUCrJ. 2024; 11(5): (17 pp.). https://doi.org/10.1107/S2052252524005608
DORA PSI

Halldórsson S, Hillringhaus L, Hojer C, Muranyi A, Schraeml M, Swiatek-de Lange M, et al.
Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen
Scientific Reports. 2024; 14(1): 16512 (11 pp.). https://doi.org/10.1038/s41598-024-67545-1
DORA PSI

Heine N, Weber A, Pautsch A, Gottschling D, Uphues I, Bauer M, et al.
Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability
Bioorganic and Medicinal Chemistry Letters. 2024; 112: 129930 (9 pp.). https://doi.org/10.1016/j.bmcl.2024.129930
DORA PSI

Hu Y, Schwab S, Deiss S, Escudeiro P, Van Heesch T, Joiner JD, et al.
Bacterial histone HBb from Bdellovibrio bacteriovorus compacts DNA by bending
Nucleic Acids Research. 2024; 52(14): 8193-8204. https://doi.org/10.1093/nar/gkae485
DORA PSI

Huang C-Y, Aumonier S, Olieric V, Wang M
Cryo2RT: a high-throughput method for room-temperature macromolecular crystallography from cryo-cooled crystals
Acta Crystallographica Section D: Structural Biology. 2024; 80(8): 620-628. https://doi.org/10.1107/S2059798324006697
DORA PSI

Huppertz M-C, Wilhelm J, Grenier V, Schneider MW, Falt T, Porzberg N, et al.
Recording physiological history of cells with chemical labeling
Science. 2024; 383(6685): 890-897. https://doi.org/10.1126/science.adg0812
DORA PSI

Igawa H, Konst ZA, Therrien E, Shelley M, Koldsø H, Bos PH, et al.
Discovery of a novel mutant-selective epidermal growth factor feceptor inhibitor using an in silico enabled drug discovery platform
Journal of Medicinal Chemistry. 2024; 67(24): 21811-21840. https://doi.org/10.1021/acs.jmedchem.4c01405
DORA PSI

Joshi T, Demmer U, Schneider C, Glaser T, Warkentin E, Ermler U, et al.
The Phosphatase RosC from Streptomyces davaonensis is Used for Roseoflavin Biosynthesis and has Evolved to Largely Prevent Dephosphorylation of the Important Cofactor Riboflavin-5′-phosphate
Journal of Molecular Biology. 2024; 436(20): 168734 (14 pp.). https://doi.org/10.1016/j.jmb.2024.168734
DORA PSI

Kageji H, Momose T, Nagamoto Y, Togashi N, Yasumatsu I, Nishikawa Y, et al.
Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation
Bioorganic and Medicinal Chemistry Letters. 2024; 98: 129575 (7 pp.). https://doi.org/10.1016/j.bmcl.2023.129575
DORA PSI

Kawano S, Kawada MI, Fukushima S, Arai Y, Shibata T, Miyano SW
Antitumor activity of Tasurgratinib as an orally available FGFR1-3 inhibitor in Cholangiocarcinoma models with FGFR2-fusion
Anticancer Research. 2024; 44(6): 2393-2406. https://doi.org/10.21873/anticanres.17046
DORA PSI

Kielkopf CS, Shneider MM, Leiman PG, Taylor NMI
T6SS-associated Rhs toxin-encapsulating shells: structural and bioinformatical insights into bacterial weaponry and self-protection
Structure. 2024; 32(12): 2375-2389.e5. https://doi.org/10.1016/j.str.2024.10.008
DORA PSI

Kotschy J, Söldner B, Singh H, Vasa SK, Linser R
Microsecond timescale conformational dynamics of a small-molecule ligand within the active site of a protein
Angewandte Chemie International Edition. 2024; 63(5): e202313947 (6 pp.). https://doi.org/10.1002/anie.202313947
DORA PSI

Kozicka Z, Suchyta DJ, Focht V, Kempf G, Petzold G, Jentzsch M, et al.
Design principles for cyclin K molecular glue degraders
Nature Chemical Biology. 2024; 20(1): 93-102. https://doi.org/10.1038/s41589-023-01409-z
DORA PSI

Kuhn B, Ritter M, Hornsperger B, Bell C, Kocer B, Rombach D, et al.
Structure-guided discovery of cis-hexahydro-pyrido-oxazinones as reversible, drug-like monoacylglycerol lipase inhibitors
Journal of Medicinal Chemistry. 2024; 67(20): 18448-18464. https://doi.org/10.1021/acs.jmedchem.4c01769
DORA PSI

Langer LM, Kurscheidt K, Basquin J, Bonneau F, Iermak I, Basquin C, et al.
UPF1 helicase orchestrates mutually exclusive interactions with the SMG6 endonuclease and UPF2
Nucleic Acids Research. 2024; 52(10): 6036-6048. https://doi.org/10.1093/nar/gkae323
DORA PSI

Langlois JB, Brenneisen S, Rodde S, Vangrevelinghe E, Rose G, Lerch P, et al.
Identification of TAK-756, a potent TAK1 inhibitor for the treatment of osteoarthritis through intra-articular administration
Journal of Medicinal Chemistry. 2024; 67(23): 21163-21185. https://doi.org/10.1021/acs.jmedchem.4c01938
DORA PSI

Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, et al.
NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations
Cancer Discovery. 2024; 14(12): 2367-2386. https://doi.org/10.1158/2159-8290.CD-24-0231
DORA PSI

Mackay A, Velcicky J, Gommermann N, Mattes H, Janser P, Wright M, et al.
Discovery of NP3-253, a potent brain penetrant inhibitor of the NLRP3 inflammasome
Journal of Medicinal Chemistry. 2024; 67(23): 20780-20798. https://doi.org/10.1021/acs.jmedchem.4c02350
DORA PSI

McCarver S, Hanna L, Samant A, Thompson AA, Seierstad M, Saha A, et al.
Structure-based optimization of selective and brain penetrant CK1δ inhibitors for the treatment of circadian disruptions
ACS Medicinal Chemistry Letters. 2024; 15(4): 486-492. https://doi.org/10.1021/acsmedchemlett.3c00523
DORA PSI

McGovern-Gooch KR, Mani N, Gotchev D, Ardzinski A, Kowalski R, Sheraz M, et al.
Biological characterization of AB-343, a novel and potent SARS-CoV-2 M^pro inhibitor with pan-coronavirus activity
Antiviral Research. 2024; 232: 106038 (9 pp.). https://doi.org/10.1016/j.antiviral.2024.106038
DORA PSI

Meibom D, Wasnaire P, Beyer K, Broehl A, Cancho-Grande Y, Elowe N, et al.
BAY-9835: discovery of the first orally bioavailable ADAMTS7 inhibitor
Journal of Medicinal Chemistry. 2024; 67(4): 2907-2940. https://doi.org/10.1021/acs.jmedchem.3c02036
DORA PSI

Melero C, Budiardjo SJ, Daruwalla A, Larrabee L, Ganichkin O, Heiler AJ, et al.
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
mAbs. 2024; 16(1): 2410316 (13 pp.). https://doi.org/10.1080/19420862.2024.2410316
DORA PSI

Meyer C, Garzia A, Miller MW, Huggins DJ, Myers RW, Hoffmann HH, et al.
Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase
Nature. 2024: e2108709118 (29 pp.). https://doi.org/10.1038/s41586-024-08320-0
DORA PSI

Mowat J, Carretero R, Leder G, Aiguabella Font N, Neuhaus R, Berndt S, et al.
Discovery of BAY-405: An azaindole-based MAP4K1 inhibitor for the enhancement of T-cell immunity against cancer
Journal of Medicinal Chemistry. 2024; 67(19): 17429-17453. https://doi.org/10.1021/acs.jmedchem.4c01325
DORA PSI

Murer P, Brannetti B, Rondeau JM, Petersen L, Egli N, Popp S, et al.
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
mAbs. 2024; 16(1): 2381891 (15 pp.). https://doi.org/10.1080/19420862.2024.2381891
DORA PSI

Münzker L, Kimani SW, Fowkes MM, Dong A, Zheng H, Li Y, et al.
A ligand discovery toolbox for the WWE domain family of human E3 ligases
Communications Biology. 2024; 7(1): 901 (15 pp.). https://doi.org/10.1038/s42003-024-06584-w
DORA PSI

Oka Y, Abe-Sato K, Tabuse H, Yasukawa Y, Yahara T, Nishimoto T, et al.
Discovery of TP0628103: A highly potent and selective MMP-7 inhibitor with reduced OATP-mediated clearance designed by shifting isoelectric points
Journal of Medicinal Chemistry. 2024; 67(2): 1406-1420. https://doi.org/10.1021/acs.jmedchem.3c01967
DORA PSI

Pala D, Clark D, Edwards C, Pasqua E, Tigli L, Pioselli B, et al.
Design and synthesis of novel 8-(azaindolyl)-benzoazepinones as potent and selective ROCK inhibitors
RSC Medicinal Chemistry. 2024; 15(11): 3862-3879. https://doi.org/10.1039/d4md00313f
DORA PSI

Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, et al.
Targeting cancer with small-molecule pan-KRAS degraders
Science. 2024; 385(6715): 1338-1347. https://doi.org/10.1126/science.adm8684
DORA PSI

Porfetye AT, Stege P, Rebollido-Rios R, Hoffmann D, Schrader T, Vetter IR
How Do molecular tweezers bind to proteins? Lessons from X-ray crystallography
Molecules. 2024; 29(8): 1764 (21 pp.). https://doi.org/10.3390/molecules29081764
DORA PSI

Schmidt M, Grethe C, Recknagel S, Kipka GM, Klink N, Gersch M
N-cyanopiperazines as specific covalent inhibitors of the deubiquitinating enzyme UCHL1
Angewandte Chemie International Edition. 2024; 63(12): e202318849 (10 pp.). https://doi.org/10.1002/anie.202318849
DORA PSI

Schneberger N, Hendricks P, Peter MF, Gehrke E, Binder SC, Koenig PA, et al.
Allosteric substrate release by a sialic acid TRAP transporter substrate binding protein
Communications Biology. 2024; 7(1): 1559 (11pp.). https://doi.org/10.1038/s42003-024-07263-6
DORA PSI

Schwab S, Hu Y, van Erp B, Cajili MKM, Hartmann MD, Hernandez Alvarez B, et al.
Histones and histone variant families in prokaryotes
Nature Communications. 2024; 15(1): 7950 (13 pp.). https://doi.org/10.1038/s41467-024-52337-y
DORA PSI

Shevalev R, Bischof L, Sapegin A, Bunev A, Olga G'eva, Kantin G, et al.
Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode
European Journal of Medicinal Chemistry. 2024; 270: 116328 (10 pp.). https://doi.org/10.1016/j.ejmech.2024.116328
DORA PSI

Skudlarek JW, Cooke AJ, Mitchell HJ, Babaoglu K, Shaw AW, Tong L, et al.
Cerastecin inhibition of the lipooligosaccharide transporter MsbA to combat Acinetobacter baumannii: from screening impurity to in Vivo efficacy
Journal of Medicinal Chemistry. 2024; 67: 15620-15675. https://doi.org/10.1021/acs.jmedchem.4c01277
DORA PSI

Solà Colom M, Fu Z, Gunkel P, Güttler T, Trakhanov S, Srinivasan V, et al.
A checkpoint function for Nup98 in nuclear pore formation suggested by novel inhibitory nanobodies
EMBO Journal. 2024; 43(11): 2198-2232. https://doi.org/10.1038/s44318-024-00081-w
DORA PSI

Swarnkar A, Leidner F, Rout AK, Ainatzi S, Schmidt CC, Becker S, et al.
Determinants of chemoselectivity in ubiquitination by the J2 family of ubiquitin-conjugating enzymes
EMBO Journal. 2024; 43: 6705-6739. https://doi.org/10.1038/s44318-024-00301-3
DORA PSI

Teuber A, Schulz T, Fletcher BS, Gontla R, Mühlenberg T, Zischinsky M-L, et al.
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
Nature Communications. 2024; 15(1): 63 (11 pp.). https://doi.org/10.1038/s41467-023-44376-8
DORA PSI

Thisted T, Smith FD, Mukherjee A, Kleschenko Y, Feng F, Jiang ZG, et al.
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
Nature Communications. 2024; 15(1): 2917 (16 pp.). https://doi.org/10.1038/s41467-024-47256-x
DORA PSI

Thoma G, Miltz W, Srinivas H, Penno CA, Kiffe M, Gajewska M, et al.
Structure-guided elaboration of a fragment-like hit into an orally efficacious leukotriene A4 hydrolase inhibitor
Journal of Medicinal Chemistry. 2024; 67(6): 5093-5108. https://doi.org/10.1021/acs.jmedchem.4c00290
DORA PSI

Toledo-Patiño S, Goetz SK, Shanmugaratnam S, Höcker B, Farías-Rico JA
Molecular handcraft of a well-folded protein chimera
FEBS Letters. 2024; 598(11): 1375-1386. https://doi.org/10.1002/1873-3468.14856
DORA PSI

Vandyck K, McGowan DC, Luong XG, Stevens SK, Jekle A, Gupta K, et al.
Discovery and preclinical profile of ALG-055009, a potent and selective thyroid hormone receptor beta (THR-β) agonist for the treatment of MASH
Journal of Medicinal Chemistry. 2024; 67: 14840-14851. https://doi.org/10.1021/acs.jmedchem.4c01029
DORA PSI

Velcicky J, Bauer MR, Schlapbach A, Lapointe G, Meyer A, Vögtle M, et al.
Discovery and In vivo exploration of 1,3,4-oxadiazole and α-fluoroacrylate containing IL-17 inhibitors
Journal of Medicinal Chemistry. 2024; 67(18): 16692-16711. https://doi.org/10.1021/acs.jmedchem.4c01520
DORA PSI

Velcicky J, Janser P, Gommermann N, Brenneisen S, Ilic S, Vangrevelinghe E, et al.
Discovery of potent, orally bioavailable, tricyclic NLRP3 inhibitors
Journal of Medicinal Chemistry. 2024; 67: 1544-1562. https://doi.org/10.1021/acs.jmedchem.3c02098
DORA PSI

Vulpetti A, Rondeau JM, Bellance MH, Blank J, Boesch R, Boettcher A, et al.
Ligandability assessment of IL-1β by integrated hit identification approaches
Journal of Medicinal Chemistry. 2024; 67: 8141-8160. https://doi.org/10.1021/acs.jmedchem.4c00240
DORA PSI

Wang X, Gotchev D, Fan KY, Vega MM, Mani N, McGovern-Gooch K, et al.
Rational design of macrocyclic noncovalent inhibitors of SARS-CoV-2 M^pro from a DNA-encoded chemical library screening hit that demonstrate potent inhibition against pan-coronavirus homologues and nirmatrelvir-resistant variants
Journal of Medicinal Chemistry. 2024. https://doi.org/10.1021/acs.jmedchem.4c02009
DORA PSI

Wendrich K, Gallant K, Recknagel S, Petroulia S, Kazi NH, Hane JA, et al.
Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53
Nature Chemical Biology. 2024; 21: 746-757. https://doi.org/10.1038/s41589-024-01777-0
DORA PSI

Abe-Sato K, Tabuse H, Kanazawa H, Kamitani M, Endo M, Tokura S, et al.
Structure-based optimization and biological evaluation of potent and selective MMP-7 inhibitors for kidney fibrosis
Journal of Medicinal Chemistry. 2023; 66(21): 14653-14668. https://doi.org/10.1021/acs.jmedchem.3c01166
DORA PSI

Adam S, Zheng D, Klein A, Volz C, Mullen W, Shirran SL, et al.
Unusual peptide-binding proteins guide pyrroloindoline alkaloid formation in crocagin biosynthesis
Nature Chemistry. 2023; 15(4): 560-568. https://doi.org/10.1038/s41557-023-01153-w
DORA PSI

Alper P, Betschart C, André C, Boulay T, Cheng D, Deane J, et al.
Discovery of the TLR7/8 antagonist MHV370 for treatment of systemic autoimmune diseases
ACS Medicinal Chemistry Letters. 2023; 14(8): 1054-1062. https://doi.org/10.1021/acsmedchemlett.3c00136
DORA PSI

Berneburg I, Stumpf M, Velten A-S, Rahlfs S, Przyborski J, Becker K, et al.
Structure of Leishmania donovani 6-phosphogluconate dehydrogenase and inhibition by phosphine gold(I) complexes: a potential approach to leishmaniasis treatment
International Journal of Molecular Sciences. 2023; 24(10): 8615 (20 pp.). https://doi.org/10.3390/ijms24108615
DORA PSI

Blum A, Dorsch D, Linde N, Brandstetter S, Buchstaller H-P, Busch M, et al.
Identification of M4205 - a highly selective inhibitor of KIT mutations for treatment of unresectable metastatic or recurrent gastrointestinal stromal tumors
Journal of Medicinal Chemistry. 2023; 66(4): 2386-2395. https://doi.org/10.1021/acs.jmedchem.2c00851
DORA PSI

Boland C, Huang C-Y, Shanker Kaki S, Wang M, Olieric V, Caffrey M
Se-MAG is a convenient additive for experimental phasing and structure determination of membrane proteins crystallised by the lipid cubic phase (in meso) method
Crystals. 2023; 13(9): 1402 (20 pp.). https://doi.org/10.3390/cryst13091402
DORA PSI

Buchstaller H-P, Sala-Hojman A, Leiendecker M, Albers J, Anlauf U, Berges N, et al.
Discovery of cycloalkyl[c]thiophenes as novel scaffolds for hypoxia-inducible factor-2α inhibitors
Journal of Medicinal Chemistry. 2023; 66(13): 8666-8686. https://doi.org/10.1021/acs.jmedchem.3c00332
DORA PSI

Bührmann M, Kallepu S, Warmuth JD, Wiese JN, Ehrt C, Vatheuer H, et al.
FRAGTORY: pharmacophore-focused design, synthesis, and evaluation of an sp³-enriched fragment library
Journal of Medicinal Chemistry. 2023; 66(9): 6297-6314. https://doi.org/10.1021/acs.jmedchem.3c00187
DORA PSI

Chen X-R, Poudel L, Hong Z, Johnen P, Katti S, Tripathi A, et al.
Mechanisms by which small molecules of diverse chemotypes arrest Sec14 lipid transfer activity
Journal of Biological Chemistry. 2023; 299(2): 102861 (21 pp.). https://doi.org/10.1016/j.jbc.2022.102861
DORA PSI

Claff T, Schlegel JG, Voss JH, Vaaßen VJ, Weiße RH, Cheng RKY, et al.
Crystal structure of adenosine A_2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction
Communications Chemistry. 2023; 6(1): 106 (10 pp.). https://doi.org/10.1038/s42004-023-00894-6
DORA PSI

Cumming JG, Kreis L, Kühne H, Wermuth R, Vercruysse M, Kramer C, et al.
Discovery of a series of indane-containing NBTIs with activity against multidrug-resistant gram-negative pathogens
ACS Medicinal Chemistry Letters. 2023; 14(7): 993-998. https://doi.org/10.1021/acsmedchemlett.3c00187
DORA PSI

De Regt AK, Anand K, Ciupka K, Bender F, Gatterdam K, Putschli B, et al.
A conserved isoleucine in the binding pocket of RIG-I controls immune tolerance to mitochondrial RNA
Nucleic Acids Research. 2023; 51(21): 11893-11910. https://doi.org/10.1093/nar/gkad835
DORA PSI

Demin S, Peschiulli A, Velter AI, Vos A, De Boeck B, Miller B, et al.
Macrocyclic carbon-linked pyrazoles as novel inhibitors of MCL-1
ACS Medicinal Chemistry Letters. 2023; 14(7): 955-961. https://doi.org/10.1021/acsmedchemlett.3c00141
DORA PSI

Dietl A, Wellach K, Mahadevan P, Mertes N, Winter SL, Kutsch T, et al.
Structures of an unusual 3-hydroxyacyl dehydratase (FabZ) from a ladderane-producing organism with an unexpected substrate preference
Journal of Biological Chemistry. 2023; 299(5): 104602 (15 pp.). https://doi.org/10.1016/j.jbc.2023.104602
DORA PSI

Dillenberger M, Werner A-D, Velten A-S, Rahlfs S, Becker K, Fritz-Wolf K
Structural analysis of Plasmodium falciparum hexokinase provides novel information about catalysis due to a Plasmodium-specific insertion
International Journal of Molecular Sciences. 2023; 24(16): 12739 (20 pp.). https://doi.org/10.3390/ijms241612739
DORA PSI

Duan J, Hemschemeier A, Burr DJ, Stripp ST, Hofmann E, Happe T
Cyanide binding to [FeFe]-hydrogenase stabilizes the alternative configuration of the proton transfer pathway
Angewandte Chemie International Edition. 2023; 62(7): e202216903 (4 pp.). https://doi.org/10.1002/anie.202216903
DORA PSI

Dunbar KL, Perlatti B, Liu N, Cornelius A, Mummau D, Chiang Y-M, et al.
Resistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases
Proceedings of the National Academy of Sciences of the United States of America PNAS. 2023; 120(48): e2310522120 (10 pp.). https://doi.org/10.1073/pnas.2310522120
DORA PSI

Duvall JR, Thomas JD, Bukhalid RA, Catcott KC, Bentley KW, Collins SD, et al.
Discovery and optimization of a STING agonist platform for application in antibody drug conjugates
Journal of Medicinal Chemistry. 2023; 66(15): 10715-10733. https://doi.org/10.1021/acs.jmedchem.3c00907
DORA PSI

Ebenhoch R, Bauer M, Romig H, Gottschling D, Kley JT, Heine N, et al.
Crystal structures of human and mouse ketohexokinase provide a structural basis for species- and isoform-selective inhibitor design
Acta Crystallographica Section D: Structural Biology. 2023; 79(10): 871-880. https://doi.org/10.1107/S2059798323006137
DORA PSI

Fedir B, Yannick M, Marco M, Patrizia F, Catherine Z, Frédéric V, et al.
N‐terminal β‐strand in YAP is critical for stronger binding to scalloped relative to TEAD transcription factor
Protein Science. 2023; 32(1): e4545 (13 pp.). https://doi.org/10.1002/pro.4545
DORA PSI

Fischman S, Levin I, Rondeau J-M, Štrajbl M, Lehmann S, Huber T, et al.
"Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A"
Communications Biology. 2023; 6(1): 997 (13 pp.). https://doi.org/10.1038/s42003-023-05369-x
DORA PSI

Gehl M, Demmer U, Ermler U, Shima S
Crystal structure of FAD-independent methylene-tetrahydrofolate reductase from Mycobacterium hassiacum
Proteins. 2023; 91(9): 1329-1340. https://doi.org/10.1002/prot.26504
DORA PSI

Goebel L, Kirschner T, Koska S, Rai A, Janning P, Maffini S, et al.
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
eLife. 2023; 12: e82184 (22 pp.). https://doi.org/10.7554/elife.82184
DORA PSI

Grabe T, Jeyakumar K, Niggenaber J, Schulz T, Koska S, Kleinbölting S, et al.
Addressing the osimertinib resistance mutation EGFR-L858R/C797S with reversible aminopyrimidines
ACS Medicinal Chemistry Letters. 2023; 14: 591-598. https://doi.org/10.1021/acsmedchemlett.2c00514
DORA PSI

Grädler U, Schwarz D, Wegener A, Eichhorn T, Bandeiras TM, Freitas MC, et al.
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
Journal of Biological Chemistry. 2023; 299(11): 105328 (14 pp.). https://doi.org/10.1016/j.jbc.2023.105328
DORA PSI

Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren J-G, et al.
Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide in clinical development
Journal of Medicinal Chemistry. 2023; 66(14): 9401-9417. https://doi.org/10.1021/acs.jmedchem.3c00623
DORA PSI

Heim C, Spring A-K, Kirchgäßner S, Schwarzer D, Hartmann MD
Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron
Biochemical and Biophysical Research Communications. 2023; 646: 30-35. https://doi.org/10.1016/j.bbrc.2023.01.051
DORA PSI

Hellweg L, Edenhofer A, Barck L, Huppertz MC, Frei MS, Tarnawski M, et al.
A general method for the development of multicolor biosensors with large dynamic ranges
Nature Chemical Biology. 2023; 19: 1147-1157. https://doi.org/10.1038/s41589-023-01350-1
DORA PSI

Hiemstra IH, Santegoets KCM, Janmaat ML, De Goeij BECG, Ten Hagen W, van Dooremalen S, et al.
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
EBioMedicine. 2023; 93: 104663 (19 pp.). https://doi.org/10.1016/j.ebiom.2023.104663
DORA PSI

Hommel U, Hurth K, Rondeau J-M, Vulpetti A, Ostermeier D, Boettcher A, et al.
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
Nature Communications. 2023; 14(1): 5497 (13 pp.). https://doi.org/10.1038/s41467-023-41190-0
DORA PSI

Imai Y, Suzuki R, Wakasugi D, Matsuda D, Tanaka-Yamamoto N, Ohki Y, et al.
Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor
Bioorganic and Medicinal Chemistry. 2023; 93: 117460 (15 pp.). https://doi.org/10.1016/j.bmc.2023.117460
DORA PSI

Jiang M, Huizenga MCW, Wirt JL, Paloczi J, Amedi A, van den Berg RJBHN, et al.
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence
Nature Communications. 2023; 14(1): 8039 (19 pp.). https://doi.org/10.1038/s41467-023-43606-3
DORA PSI

Kalliokoski T, Kettunen H, Kumpulainen E, Kettunen E, Thieulin-Pardo G, Neumann L, et al.
Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening
Bioorganic and Medicinal Chemistry Letters. 2023; 94: 129450 (8 pp.). https://doi.org/10.1016/j.bmcl.2023.129450
DORA PSI

Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, et al.
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Nature. 2023; 619(7968): 160-166. https://doi.org/10.1038/s41586-023-06123-3
DORA PSI

Kompa J, Bruins J, Glogger M, Wilhelm J, Frei MS, Tarnawski M, et al.
Exchangeable HaloTag ligands for super-resolution fluorescence microscopy
Journal of the American Chemical Society. 2023; 145(5): 3075-3083. https://doi.org/10.1021/jacs.2c11969
DORA PSI

Krasavin M, Adamchik M, Bubyrev A, Heim C, Maiwald S, Zhukovsky D, et al.
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines
European Journal of Medicinal Chemistry. 2023; 246: 114990 (12 pp.). https://doi.org/10.1016/j.ejmech.2022.114990
DORA PSI

Krieger J, Sorrell FJ, Wegener AA, Leuthner B, Machrouhi-Porcher F, Hecht M, et al.
Systematic potency and property assessment of VHL ligands and implications on PROTAC design
ChemMedChem. 2023; 18(8): e202200615 (11 pp.). https://doi.org/10.1002/cmdc.202200615
DORA PSI

Kuhn B, Ritter M, Benz J, Kocer B, Sarie JC, Hochstrasser R, et al.
Novel potent and highly selective DDR1 inhibitors from integrated lead finding
Medicinal Chemistry Research. 2023; 32(7): 1400-1425. https://doi.org/10.1007/s00044-023-03066-2
DORA PSI

Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, et al.
Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279
Journal of Medicinal Chemistry. 2023; 66: 10473-10496. https://doi.org/10.1021/acs.jmedchem.3c00600
DORA PSI

Liu J, Chiang H-C, Xiong W, Laurent V, Griffiths SC, Dülfer J, et al.
A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer
Journal for ImmunoTherapy of Cancer. 2023; 11(6): e006720 (14 pp.). https://doi.org/10.1136/jitc-2023-006720
DORA PSI

Martinelli P, Schaaf O, Mantoulidis A, Martin LJ, Fuchs JE, Bader G, et al.
Discovery of a chemical probe to study implications of BPTF bromodomain inhibition in cellular and in vivo experiments
ChemMedChem. 2023; 18(6): e202200686 (8 pp.). https://doi.org/10.1002/cmdc.202200686
DORA PSI

Mauxion F, Basquin J, Ozgur S, Rame M, Albrecht J, Schäfer I, et al.
The human CNOT1-CNOT10-CNOT11 complex forms a structural platform for protein-protein interactions
Cell Reports. 2023; 42(1): 111902 (18 pp.). https://doi.org/10.1016/j.celrep.2022.111902
DORA PSI

Mesrouze Y, Gubler H, Villard F, Boesch R, Ottl J, Kallen J, et al.
Biochemical and structural characterization of a peptidic inhibitor of the YAP:TEAD interaction that binds to the α-Helix Pocket on TEAD
ACS Chemical Biology. 2023; 18(3): 643-651. https://doi.org/10.1021/acschembio.2c00936
DORA PSI

Mhaindarkar VP, Rasche R, Kümmel D, Rudolph MG, Klostermeier D
Structure of reverse gyrase with a minimal latch that supports ATP-dependent positive supercoiling without specific interactions with the topoisomerase domain
Acta Crystallographica Section D: Structural Biology. 2023; 79(6): 498-507. https://doi.org/10.1107/S2059798323002565
DORA PSI

Miyagi H, Suzuki M, Yasunaga M, Asada H, Iwata S, Saito J-ichi
Structural insight into an anti-BRIL Fab as a G-protein-coupled receptor crystallization chaperone
Acta Crystallographica Section D: Structural Biology. 2023; 79(5): 435-441. https://doi.org/10.1107/S205979832300311X
DORA PSI

Nain-Perez A, Nilsson O, Lulla A, Håversen L, Brear P, Liljenberg S, et al.
Tuning liver pyruvate kinase activity up or down with a new class of allosteric modulators
European Journal of Medicinal Chemistry. 2023; 250: 115177 (18 pp.). https://doi.org/10.1016/j.ejmech.2023.115177
DORA PSI

Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, et al.
Validation of a new methodology to create oral drugs beyond the rule of 5 for intracellular tough targets
Journal of the American Chemical Society. 2023; 145(44): 24035-24051. https://doi.org/10.1021/jacs.3c07145
DORA PSI

O’Dea R, Kazi N, Hoffmann-Benito A, Zhao Z, Recknagel S, Wendrich K, et al.
Molecular basis for ubiquitin/Fubi cross-reactivity in USP16 and USP36
Nature Chemical Biology. 2023; 19(11): 1394-1405. https://doi.org/10.1038/s41589-023-01388-1
DORA PSI

Roehrig S, Ackerstaff J, Jiménez Núñez E, Teller H, Ellerbrock P, Meier K, et al.
Design and preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders
Journal of Medicinal Chemistry. 2023; 66(17): 12203-12224. https://doi.org/10.1021/acs.jmedchem.3c00795
DORA PSI

Romanov-Michailidis F, Hsiao C-C, Urner LM, Jerhaoui S, Surkyn M, Miller B, et al.
Discovery of an oral, beyond-rule-of-five Mcl-1 protein-protein interaction modulator with the potential of treating hematological malignancies
Journal of Medicinal Chemistry. 2023; 66(9): 6122-6148. https://doi.org/10.1021/acs.jmedchem.2c01953
DORA PSI

Rutz S, Deneka D, Dittmann A, Sawicka M, Dutzler R
Structure of a volume-regulated heteromeric LRRC8A/C channel
Nature Structural and Molecular Biology. 2023; 30: 52-61. https://doi.org/10.1038/s41594-022-00899-0
DORA PSI

Schmeing S, Amrahova G, Bigler K, Chang JY, Openy J, Pal S, et al.
Rationally designed stapled peptides allosterically inhibit PTBP1-RNA-binding
Chemical Science. 2023; 14(31): 8269-8278. https://doi.org/10.1039/d3sc00985h
DORA PSI

Schröder M, Leiendecker M, Grädler U, Braun J, Blum A, Wanior M, et al.
MSC-1186, a highly selective Pan-SRPK inhibitor based on an exceptionally decorated benzimidazole-pyrimidine core
Journal of Medicinal Chemistry. 2023; 66(1): 837-854. https://doi.org/10.1021/acs.jmedchem.2c01705
DORA PSI

Selim KA, Haffner M, Mantovani O, Albrecht R, Zhu H, Hagemann M, et al.
Carbon signaling protein SbtB possesses atypical redox-regulated apyrase activity to facilitate regulation of bicarbonate transporter SbtA
Proceedings of the National Academy of Sciences of the United States of America PNAS. 2023; 120(8): e2205882120 (11 pp.). https://doi.org/10.1073/pnas.2205882120
DORA PSI

Sellner H, Chapeau E, Furet P, Voegtle M, Salem B, Le Douget M, et al.
Optimization of a class of dihydrobenzofurane analogs toward orally efficacious YAP-TEAD protein-protein interaction inhibitors
ChemMedChem. 2023; 18(11): e202300051 (23 pp.). https://doi.org/10.1002/cmdc.202300051
DORA PSI

Sikandar A, Popoff A, Jumde RP, Mándi A, Kaur A, Elgaher WAM, et al.
Revision of the absolute configurations of chelocardin and amidochelocardin
Angewandte Chemie International Edition. 2023; 62(40): e202306437 (5 pp.). https://doi.org/10.1002/anie.202306437
DORA PSI

Smith KML, Panepucci E, Kaminski JW, Aumonier S, Huang C-Y, Eris D, et al.
SDU - software for high-throughput automated data collection at the Swiss Light Source
Journal of Synchrotron Radiation. 2023; 30: 538-545. https://doi.org/10.1107/S1600577523002631
DORA PSI

Spiller L, Manjula R, Leissing F, Basquin J, Bourilhon P, Sinitski D, et al.
Plant MDL proteins synergize with the cytokine MIF at CXCR2 and CXCR4 receptors in human cells
Science Signaling. 2023; 16(812): eadg2621 (18 pp.). https://doi.org/10.1126/scisignal.adg2621
DORA PSI

Stegmann DP, Steuber J, Fritz G, Wojdyla JA, Sharpe ME
Fast fragment and compound screening pipeline at the Swiss Light Source
In: Methods in enzymology. sine loco: Elsevier; 2023:235-284. https://doi.org/10.1016/bs.mie.2023.08.005
DORA PSI

Steinebach C, Bricelj A, Murgai A, Sosič I, Bischof L, Ng YLD, et al.
Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs
Journal of Medicinal Chemistry. 2023; 66(21): 14513-14543. https://doi.org/10.1021/acs.jmedchem.3c00851
DORA PSI

Stephan P, Langley C, Winkler D, Basquin J, Caputi L, O'Connor SE, et al.
Directed evolution of piperazic acid incorporation by a nonribosomal peptide synthetase**
Angewandte Chemie International Edition. 2023; 62(35): e202304843 (6 pp.). https://doi.org/10.1002/anie.202304843
DORA PSI

Thoma G, Markert C, Lueoend R, Miltz W, Spanka C, Bollbuck B, et al.
Discovery of amino alcohols as highly potent, selective, and orally efficacious inhibitors of leukotriene A4 hydrolase
Journal of Medicinal Chemistry. 2023; 66: 16410-16425. https://doi.org/10.1021/acs.jmedchem.3c01866
DORA PSI

Toure M, Johnson T, Li B, Schmidt R, Ma H, Neagu C, et al.
Discovery of quinazoline HPK1 inhibitors with high cellular potency
Bioorganic and Medicinal Chemistry. 2023; 92: 117423 (16 pp.). https://doi.org/10.1016/j.bmc.2023.117423
DORA PSI

Valiente-Gabioud AA, Garteizgogeascoa Suñer I, Idziak A, Fabritius A, Basquin J, Angibaud J, et al.
Fluorescent sensors for imaging of interstitial calcium
Nature Communications. 2023; 14(1): 6220 (15 pp.). https://doi.org/10.1038/s41467-023-41928-w
DORA PSI

Vulpetti A, Holzer P, Schmiedeberg N, Imbach-Weese P, Pissot-Soldermann C, Hollingworth GJ, et al.
Discovery of new binders for DCAF1, an emerging ligase target in the targeted protein degradation field
ACS Medicinal Chemistry Letters. 2023; 14(7): 949-954. https://doi.org/10.1021/acsmedchemlett.3c00104
DORA PSI

Zhao Z, O’Dea R, Wendrich K, Kazi N, Gersch M
Native semisynthesis of isopeptide-linked substrates for specificity analysis of deubiquitinases and Ubl proteases
Journal of the American Chemical Society. 2023; 145(38): 20801-20812. https://doi.org/10.1021/jacs.3c04062
DORA PSI

Altegoer F, Quax TEF, Weiland P, Nußbaum P, Giammarinaro PI, Patro M, et al.
Structural insights into the mechanism of archaellar rotational switching
Nature Communications. 2022; 13(1): 2857 (12 pp.). https://doi.org/10.1038/s41467-022-30358-9
DORA PSI

Astashkin R, Kovalev K, Bukhdruker S, Vaganova S, Kuzmin A, Alekseev A, et al.
Structural insights into light-driven anion pumping in cyanobacteria
Nature Communications. 2022; 13(1): 6460 (13 pp.). https://doi.org/10.1038/s41467-022-34019-9
DORA PSI

Aziz I, Kaltwasser S, Kayastha K, Khera R, Vonck J, Ermler U
The molybdenum storage protein forms and deposits distinct polynuclear tungsten oxygen aggregates
Journal of Inorganic Biochemistry. 2022; 234: 111904 (9 pp.). https://doi.org/10.1016/j.jinorgbio.2022.111904
DORA PSI

Berneburg I, Rahlfs S, Becker K, Fritz-Wolf K
Crystal structure of Leishmania donovani glucose 6-phosphate dehydrogenase reveals a unique N-terminal domain
Communications Biology. 2022; 5(1): 1353 (14 pp.). https://doi.org/10.1038/s42003-022-04307-7
DORA PSI

Beroza P, Crawford JJ, Ganichkin O, Gendelev L, Harris SF, Klein R, et al.
Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors
Nature Communications. 2022; 13(1): 6447 (10 pp.). https://doi.org/10.1038/s41467-022-33981-8
DORA PSI

Betschart C, Faller M, Zink F, Hemmig R, Blank J, Vangrevelinghe E, et al.
Structure-based optimization of a fragment-like TLR8 binding screening hit to an in vivo efficacious TLR7/8 antagonist
ACS Medicinal Chemistry Letters. 2022; 13(4): 658-664. https://doi.org/10.1021/acsmedchemlett.1c00696
DORA PSI

Botte M, Ni D, Schenck S, Zimmermann I, Chami M, Bocquet N, et al.
Cryo-EM structures of a LptDE transporter in complex with Pro-macrobodies offer insight into lipopolysaccharide translocation
Nature Communications. 2022; 13(1): 1826 (10 pp.). https://doi.org/10.1038/s41467-022-29459-2
DORA PSI

Bröker J, Waterson AG, Smethurst C, Kessler D, Böttcher J, Mayer M, et al.
Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRAS^G12C inhibitor
Journal of Medicinal Chemistry. 2022; 65(21): 14614-14629. https://doi.org/10.1021/acs.jmedchem.2c01120
DORA PSI

Carvalho LAR, Ross B, Fehr L, Bolgi O, Wöhrle S, Lum KM, et al.
Chemoproteomics-enabled identification of 4-Oxo-β-lactams as inhibitors of dipeptidyl peptidases 8 and 9
Angewandte Chemie International Edition. 2022; 61(47): e202210498 (10 pp.). https://doi.org/10.1002/anie.202210498
DORA PSI

Chakrabarti KS, Olsson S, Pratihar S, Giller K, Overkamp K, Lee KO, et al.
A litmus test for classifying recognition mechanisms of transiently binding proteins
Nature Communications. 2022; 13(1): 3792 (11 pp.). https://doi.org/10.1038/s41467-022-31374-5
DORA PSI

Chrustowicz J, Sherpa D, Teyra J, Loke MS, Popowicz GM, Basquin J, et al.
Multifaceted N-degron recognition and ubiquitylation by GID/CTLH E3 ligases
Journal of Molecular Biology. 2022; 434(2): 167347 (22 pp.). https://doi.org/10.1016/j.jmb.2021.167347
DORA PSI

Cisar JS, Pietsch C, DeRatt LG, Jacoby E, Kazmi F, Keohane C, et al.
N-heterocyclic 3-pyridyl carboxamide inhibitors of DHODH for the treatment of acute myelogenous leukemia
Journal of Medicinal Chemistry. 2022; 65(16): 11241-11256. https://doi.org/10.1021/acs.jmedchem.2c00788
DORA PSI

Dahms SO, Schnapp G, Winter M, Büttner FH, Schlepütz M, Gnamm C, et al.
Dichlorophenylpyridine-based molecules inhibit furin through an induced-fit mechanism
ACS Chemical Biology. 2022; 17(4): 816-821. https://doi.org/10.1021/acschembio.2c00103
DORA PSI

Davies C, Dötsch L, Ciulla MG, Hennes E, Yoshida K, Gasper R, et al.
Identification of a novel pseudo‐natural product type IV IDO1 inhibitor chemotype
Angewandte Chemie International Edition. 2022; 61(40): e202209374 (12 pp.). https://doi.org/10.1002/anie.202209374
DORA PSI

Diaz E, Adhikary S, Tepper AWJW, Riley D, Ortiz-Meoz R, Krosky D, et al.
Structure of human spermine oxidase in complex with a highly selective allosteric inhibitor
Communications Biology. 2022; 5(1): 787 (14 pp.). https://doi.org/10.1038/s42003-022-03735-9
DORA PSI

Dillenberger M, Rahlfs S, Becker K, Fritz-Wolf K
Prominent role of cysteine residues C49 and C343 in regulating Plasmodium falciparum pyruvate kinase activity
Structure. 2022; 30(10): 1452-1461.e3. https://doi.org/10.1016/j.str.2022.08.001
DORA PSI

Fairhurst RA, Furet P, Imbach-Weese P, Stauffer F, Rueeger H, McCarthy C, et al.
Identification of NVP-CLR457 as an orally bioavailable Non-CNS-Penetrant pan-class IA phosphoinositol-3-kinase inhibitor
Journal of Medicinal Chemistry. 2022; 65(12): 8345-8379. https://doi.org/10.1021/acs.jmedchem.2c00267
DORA PSI

Frei MS, Tarnawski M, Roberti MJ, Koch B, Hiblot J, Johnsson K
Engineered HaloTag variants for fluorescence lifetime multiplexing
Nature Methods. 2022; 19(1): 65-70. https://doi.org/10.1038/s41592-021-01341-x
DORA PSI

Fritz-Wolf K, Bathke J, Rahlfs S, Becker K
Crystal structure of plasmoredoxin, a redox-active protein unique for malaria parasites
Current Research in Structural Biology. 2022; 4: 87-95. https://doi.org/10.1016/j.crstbi.2022.03.004
DORA PSI

Furet P, Bordas V, Le Douget M, Salem B, Mesrouze Y, Imbach-Weese P, et al.
The first class of small molecules potently disrupting the YAP-TEAD interaction by direct competition
ChemMedChem. 2022; 17(19): e202200303 (14 pp.). https://doi.org/10.1002/cmdc.202200303
DORA PSI

Gao L, Meiring JCM, Varady A, Ruider IE, Heise C, Wranik M, et al.
In vivo photocontrol of microtubule dynamics and integrity, migration and mitosis, by the potent GFP-imaging-compatible photoswitchable reagents SBTubA4P and SBTub2M
Journal of the American Chemical Society. 2022; 144(12): 5614-5628. https://doi.org/10.1021/jacs.2c01020
DORA PSI

Gehrtz P, Marom S, Bührmann M, Hardick J, Kleinbölting S, Shraga A, et al.
Optimization of covalent MKK7 inhibitors via crude nanomole-scale libraries
Journal of Medicinal Chemistry. 2022; 65(15): 10341-10356. https://doi.org/10.1021/acs.jmedchem.1c02206
DORA PSI

Goepfert A, Barske C, Lehmann S, Wirth E, Willemsen J, Gudjonsson JE, et al.
IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling
Cell Reports. 2022; 41(3): 111489 (19 pp.). https://doi.org/10.1016/j.celrep.2022.111489
DORA PSI

Grethe C, Schmidt M, Kipka G-M, O’Dea R, Gallant K, Janning P, et al.
Structural basis for specific inhibition of the deubiquitinase UCHL1
Nature Communications. 2022; 13(1): 5950 (17 pp.). https://doi.org/10.1038/s41467-022-33559-4
DORA PSI

Heim C, Hartmann MD
High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
Acta Crystallographica Section D: Structural Biology. 2022; 78: 290-298. https://doi.org/10.1107/S2059798322000092
DORA PSI

Heim C, Spring AK, Kirchgäßner S, Schwarzer D, Hartmann MD
Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
Biochemical and Biophysical Research Communications. 2022; 637: 66 (7 pp.)-72. https://doi.org/10.1016/j.bbrc.2022.11.001
DORA PSI

Heimsch KC, Gertzen CGW, Schuh AK, Nietzel T, Rahlfs S, Przyborski JM, et al.
Structure and function of redox-sensitive superfolder green fluorescent protein variant
Antioxidants and Redox Signaling. 2022; 37(1-3): 1-18. https://doi.org/10.1089/ars.2021.0234
DORA PSI

Hernández Lozada NJ, Hong B, Wood JC, Caputi L, Basquin J, Chuang L, et al.
Biocatalytic routes to stereo-divergent iridoids
Nature Communications. 2022; 13(1): 4718 (13 pp.). https://doi.org/10.1038/s41467-022-32414-w
DORA PSI

Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, et al.
Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies
Journal of Medicinal Chemistry. 2022; 65(7): 5317-5333. https://doi.org/10.1021/acs.jmedchem.1c02148
DORA PSI

Huang C-Y, Aumonier S, Engilberge S, Eris D, Smith KML, Leonarski F, et al.
Probing ligand binding of endothiapepsin by 'temperature-resolved' macromolecular crystallography
Acta Crystallographica Section D: Structural Biology. 2022; 78: 964-974. https://doi.org/10.1107/S205979832200612X
DORA PSI

Hunziker D, Reinehr S, Palmhof M, Wagner N, Biniasch T, Stute G, et al.
Synthesis, characterization, and in vivo evaluation of a novel potent autotaxin-inhibitor
Frontiers in Pharmacology. 2022; 12: 699535 (24 pp.). https://doi.org/10.3389/fphar.2021.699535
DORA PSI

Huyton T, Jaiswal M, Taxer W, Fischer M, Görlich D
Crystal structures of FNIP/FGxxFN motif-containing leucine-rich repeat proteins
Scientific Reports. 2022; 12(1): 16430 (12 pp.). https://doi.org/10.1038/s41598-022-20758-8
DORA PSI

Iskhakova ZI, Zhuravleva DE, Heim C, Hartmann MD, Laykov AV, Forchhammer K, et al.
PotN represents a novel energy-state sensing PII subfamily, occurring in firmicutes
FEBS Journal. 2022; 289(17): 5305-5321. https://doi.org/10.1111/febs.16431
DORA PSI

Kemble AM, Hornsperger B, Ruf I, Richter H, Benz J, Kuhn B, et al.
A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature
PLoS One. 2022; 17(9): e0268590 (24 pp.). https://doi.org/10.1371/journal.pone.0268590
DORA PSI

Kofink C, Trainor N, Mair B, Wöhrle S, Wurm M, Mischerikow N, et al.
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
Nature Communications. 2022; 13(1): 5969 (15 pp.). https://doi.org/10.1038/s41467-022-33430-6
DORA PSI

Krasavin M, Bubyrev A, Kazantsev A, Heim C, Maiwald S, Zhukovsky D, et al.
Replacing the phthalimide core in thalidomide with benzotriazole
Journal of Enzyme Inhibition and Medicinal Chemistry. 2022; 37(1): 527-530. https://doi.org/10.1080/14756366.2021.2024525
DORA PSI

Kubacka D, Kozarski M, Baranowski MR, Wojcik R, Panecka‐Hofman J, Strzelecka D, et al.
Substrate‐based design of cytosolic nucleotidase IIIB inhibitors and structural insights into inhibition mechanism
Pharmaceuticals. 2022; 15(5): 554 (27 pp.). https://doi.org/10.3390/ph15050554
DORA PSI

Ladduwahetty T, Lee MR, Maillard MC, Cachope R, Todd D, Barnes M, et al.
Identification of a potent, selective, and brain-penetrant Rho kinase inhibitor and its activity in a mouse model of Huntington's disease
Journal of Medicinal Chemistry. 2022; 65(14): 9819-9845. https://doi.org/10.1021/acs.jmedchem.2c00474
DORA PSI

Langley C, Tatsis E, Hong B, Nakamura Y, Paetz C, Stevenson CEM, et al.
Expansion of the catalytic repertoire of alcohol dehydrogenases in plant metabolism
Angewandte Chemie International Edition. 2022; 61(48): e202210934 (7 pp.). https://doi.org/10.1002/anie.202210934
DORA PSI

Langlois CR, Beier V, Karayel O, Chrustowicz J, Sherpa D, Mann M, et al.
A GID E3 ligase assembly ubiquitinates an Rsp5 E3 adaptor and regulates plasma membrane transporters
EMBO Reports. 2022; 23(6): e53835 (17 pp.). https://doi.org/10.15252/embr.202153835
DORA PSI

Langousis G, Sanchez J, Kempf G, Matthias P
Expression and crystallization of HDAC6 tandem catalytic domains
In: Krämer OH, ed. HDAC/HAT function assessment and inhibitor development. Methods and protocols. Methods in molecular biology. New York: Humana; 2022:467-480. https://doi.org/10.1007/978-1-0716-2788-4_30
DORA PSI

Lategahn J, Tumbrink HL, Schultz-Fademrecht C, Heimsoeth A, Werr L, Niggenaber J, et al.
Insight into targeting exon20 insertion mutations of the epidermal growth factor receptor with wild type-sparing inhibitors
Journal of Medicinal Chemistry. 2022; 65(9): 6643-6655. https://doi.org/10.1021/acs.jmedchem.1c02080
DORA PSI

Li D, Sloman DL, Achab A, Zhou H, McGowan MA, White C, et al.
Oxetane promise delivered: discovery of long-acting IDO1 inhibitors suitable for Q3W oral or parenteral dosing
Journal of Medicinal Chemistry. 2022; 65(8): 6001-6016. https://doi.org/10.1021/acs.jmedchem.1c01670
DORA PSI

Lorthiois E, Gerspacher M, Beyer KS, Vaupel A, Leblanc C, Stringer R, et al.
JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS^G12C for the treatment of solid tumors
Journal of Medicinal Chemistry. 2022; 65(24): 16173-16203. https://doi.org/10.1021/acs.jmedchem.2c01438
DORA PSI

Luebben AV, Bender D, Becker S, Crowther LM, Erven I, Hofmann K, et al.
Cln5 represents a new type of cysteine-based S-depalmitoylase linked to neurodegeneration
Science Advances. 2022; 8(15): eabj8633 (10 pp.). https://doi.org/10.1126/sciadv.abj8633
DORA PSI

Mata G, Miles DH, Drew SL, Fournier J, Lawson KV, Mailyan AK, et al.
Design, synthesis, and structure-activity relationship optimization of pyrazolopyrimidine amide inhibitors of phosphoinositide 3-kinase γ (PI3Kγ)
Journal of Medicinal Chemistry. 2022; 65(2): 1418-1444. https://doi.org/10.1021/acs.jmedchem.1c01153
DORA PSI